Ritholtz Wealth Management raised its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 130.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 831,091 shares of the biotechnology company’s stock after buying an additional 470,997 shares during the quarter. Ritholtz Wealth Management’s holdings in Ironwood Pharmaceuticals were worth $3,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $40,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Ironwood Pharmaceuticals in the first quarter worth $47,000. Bull Harbor Capital LLC bought a new position in shares of Ironwood Pharmaceuticals during the first quarter worth $48,000. Ascent Group LLC bought a new position in shares of Ironwood Pharmaceuticals during the third quarter worth $58,000. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Ironwood Pharmaceuticals during the first quarter worth $65,000.
Ironwood Pharmaceuticals Stock Performance
IRWD stock opened at $4.83 on Monday. The firm has a fifty day moving average price of $3.97 and a 200 day moving average price of $3.96. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $2.95 and a fifty-two week high of $5.78. The firm has a market cap of $799.61 million, a PE ratio of 5.37 and a beta of 0.25.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. The company had revenue of $133.04 million for the quarter, compared to analysts’ expectations of $119.99 million. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. On average, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.10 EPS for the current year.
Analyst Upgrades and Downgrades
IRWD has been the subject of several research reports. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Finally, Jefferies Financial Group raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $6.23.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
